CAS |
486460-32-6 |
Chinese Name |
西他列汀 |
English Name |
Sitagliptin |
Synonym |
MK0431 |
Unit |
Bottle |
Purity |
≥98% |
Molecular Formula |
C16H15F6N5O |
Molecular Weight |
407.31 |
Appearance |
White to off-white solid |
Storage |
Powder : 2-8℃, 2 years; In solvent(mother liquid): -20℃, 1 month; -80℃, 6 months |
Solubility |
Soluble in water≥10mg/ml, soluble in DMSO≥25mg/ml(Need ultrasound or water bath) |
EC |
EINECS 690-730-1 |
MDL |
MFCD19684081 |
InChIKey |
MFFMDFFZMYYVKS-SECBINFHSA-N |
InChI |
InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1 |
PubChem CID |
4369359 |
SMILES |
O=C(N1CC2=NN=C(C(F)(F)F)N2CC1)C[C@H](N)CC3=CC(F)=C(F)C=C3F |
Description |
Sitagliptin is a potent DPP4 inhibitor |
Target Point |
Dipeptidyl Peptidase (DPP) |
Passage |
Metabolic Enzyme&Protease |
Data Literature Source |
[1]. Thomas, L., et al. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008 Apr;325(1):175-82.
[2]. Kim, S.J., et al., Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes, 2009. 58(3): p. 641-51.
[3]. Sangle, G.V., et al., Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue. Endocrinology, 2012. 153(2): p. 564-73.
[4]. Kim, S.J., et al., Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes, 2008. 57(5): p. 1331-9.
[5]. Beconi, M.G., et al. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab Dispos, 2007. 35(4): p. 525-32. |
Specification |
50mg 10mM*1mL (in DMSO) 100mg |